Great West Life Assurance Co. Can continued to hold its position in shares of AveXis, Inc. (NASDAQ:AVXS) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,800 shares of the company’s stock at the close of the 2nd quarter. Great West Life Assurance Co. Can’s holdings in AveXis were worth $148,000 as of its most recent filing with the SEC.
Several other large investors have also recently added to or reduced their stakes in AVXS. Nationwide Fund Advisors grew its holdings in shares of AveXis by 9.0% during the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock worth $262,000 after purchasing an additional 284 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of AveXis by 30.2% during the first quarter. Russell Investments Group Ltd. now owns 17,550 shares of the company’s stock worth $1,335,000 after purchasing an additional 4,067 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of AveXis by 27.8% during the first quarter. Bank of New York Mellon Corp now owns 62,922 shares of the company’s stock worth $4,784,000 after purchasing an additional 13,691 shares during the last quarter. Swiss National Bank grew its holdings in shares of AveXis by 3.0% during the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock worth $2,083,000 after purchasing an additional 800 shares during the last quarter. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of AveXis during the first quarter worth about $297,000. Institutional investors own 94.71% of the company’s stock.
Shares of AveXis, Inc. (AVXS) opened at 88.08 on Friday. The company’s market capitalization is $2.81 billion. AveXis, Inc. has a one year low of $38.46 and a one year high of $99.45. The company has a 50-day moving average price of $93.12 and a 200 day moving average price of $80.06.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same period last year, the company posted ($0.68) earnings per share. Equities analysts anticipate that AveXis, Inc. will post ($6.04) EPS for the current year.
In related news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $93.25, for a total transaction of $165,985.00. Following the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $165,985. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 5,340 shares of company stock worth $474,637. 18.60% of the stock is owned by corporate insiders.
Several analysts have recently weighed in on AVXS shares. Jefferies Group LLC restated a “buy” rating and set a $108.00 price target (up from $92.00) on shares of AveXis in a report on Friday, August 11th. Chardan Capital restated a “buy” rating and set a $130.00 price target (up from $102.50) on shares of AveXis in a report on Friday, August 11th. BMO Capital Markets restated a “buy” rating and set a $123.00 price target on shares of AveXis in a report on Friday, August 11th. Citigroup Inc. set a $100.00 price target on AveXis and gave the stock a “buy” rating in a report on Thursday, June 15th. Finally, Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $99.29.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.